glp 3 rt vs glp 1 Beyond GLP-1: Retatrutide's triple-agonist mechanism (GLP-1, GIP, glucagon) is redefining metabolic health. Phase 2 data shows ~24% weight loss—surpassing semaglutide & tirzepatide. Evidence-based protocols demand nutrition support alongside prescribing Summer is coming, and peptides
Description
In SOUL, composite HF endpoints were analysed as a secondary outcome, with oral semaglutide resulting in a non-significant reduction in HF events
That stands out
Need help deciding
The following recommendations are based on MHRA-approved product information and manufacturer instructions
